Folate receptor alpha: a new tool in the diagnosis and treatment of lung cancer.
In their study of FRA in lung adenocarcinoma, O'Shannessy et al employed rigorous validation of a potentially useful clinical tool--using an immunohistochemical assay with a specific monoclonal antibody, they show that FRA expression is relatively specific for lung adenocarcinoma and that high FRA expression is associated with improved survival. Though further work will be necessary to translate this assay (and the related targeted therapy) into human cancer patients, their study confirmed the potential of FRA as a prognostic marker in lung adenocarcinoma.
Laura D
LD
Wood
D002289:Carcinoma, Non-Small-Cell Lung / Q000175:diagnosis* / Q000401:mortality*; D005260:Female; D058975:Folate Receptor 1 / Q000378:metabolism*; D006801:Humans; D008175:Lung Neoplasms / Q000175:diagnosis* / Q000401:mortality*; D008297:Male
D058975:Folate Receptor 1